|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM064400581 |
| 003 |
DE-627 |
| 005 |
20231221225705.0 |
| 007 |
tu |
| 008 |
231221s1984 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0215.xml
|
| 035 |
|
|
|a (DE-627)NLM064400581
|
| 035 |
|
|
|a (NLM)6463065
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Head, A C
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A multi-centre, general practice assessment of a timolol/bendrofluazide combination ('Prestim') in the treatment of mild to moderate hypertension
|
| 264 |
|
1 |
|c 1984
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.09.1984
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A fixed dose combination of 10 mg timolol and 2.5 mg bendrofluazide was evaluated in 1640 general practice patients with mild to moderate hypertension. This was an open study lasting 3 months with an initial 2-week placebo controlled run-in phase. Of the 1315 patients who were evaluable, 1169 (89%) became normotensive on a mean single daily dose of 1.75 tablets. Fifty-four (4%) patients were uncontrolled on a maximum dose of 4 tablets daily and 79 (6%) patients stopped therapy prematurely due to side-effects. A further 13 (1%) patients withdrew because of hypotension or bradycardia. Biochemical parameters stayed within normal values. Overall, the results showed that the combination of timolol and bendrofluazide was an effective and well accepted treatment for mild to moderate hypertension in a large and varied general practice population
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antihypertensive Agents
|2 NLM
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a Bendroflumethiazide
|2 NLM
|
| 650 |
|
7 |
|a 5Q52X6ICJI
|2 NLM
|
| 650 |
|
7 |
|a prestim
|2 NLM
|
| 650 |
|
7 |
|a 74335-22-1
|2 NLM
|
| 650 |
|
7 |
|a Timolol
|2 NLM
|
| 650 |
|
7 |
|a 817W3C6175
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1984), 10 vom: 20., Seite 650-6
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:3
|g year:1984
|g number:10
|g day:20
|g pages:650-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 1984
|e 10
|b 20
|h 650-6
|